---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102985"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:52:07.267296+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q2 2025 rev $110.6M, Attruby sales $71.5M, net loss $181.9M

## Summary
- Total revenue $110.6M vs $2.2M prior year; Attruby net product revenue $71.5M.
- Net loss attributable to common stockholders $181.9M ($0.95 EPS) vs $73.5M ($0.39 EPS) prior year.
- As of Aug 1, 2025, 3,751 unique patient prescriptions for Attruby by 1,074 prescribers; launch accelerating.
- Pipeline: FORTIFY (LGMD2I/R9) and CALIBRATE (ADH1) topline results expected fall 2025; PROPEL 3 (achondroplasia) early 2026.
- Cash, cash equivalents and marketable securities $756.9M; raised $300M via royalty sale.

## SEC filing metadata
- accession: 0000950170-25-102985
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/0000950170-25-102985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/bbio-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102985
- JSON: https://secwatch.observer/filing/0000950170-25-102985.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.